Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. - Wikidata - awgldk - TriplyDB

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

http://www.wikidata.org/entity/Q37695495

about

Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines Efficacy of eribulin in breast cancer: a short report on the emerging new data.Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.Eribulin for heavily pre-treated metastatic breast cancer patients Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients.Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.Eribulin in the treatment of breast cancer: an important weapon in the treatment algorithm.Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.Drug-induced hepatotoxicity in cancer patients - implication for treatment.A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.Eribulin in advanced breast cancer: safety, efficacy and new perspectives.Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin.Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).

P2860

Q28080469-FEB0D5B6-C8ED-44B0-8D7A-076F509451CB Q31167441-2A918349-C9EA-4D33-9184-F7EF74E15002 Q33426567-77B5CC76-67BC-4B40-AC3B-59C53F997AFC Q35756426-2BB78921-B294-40F4-8B31-F7F02C65860A Q36234055-802AC275-1027-4EDD-AE66-DC93B3C8DA2B Q36484243-19E2D952-6DDF-443F-AE38-DDDD0E1E4A4D Q36742259-5343B320-A76F-4EA7-B43C-BE1970EAC8F7 Q38686619-C4FE023D-5974-42D8-B855-8C744A0923D8 Q38686622-BCEF6ED4-0FBD-4A42-B536-9D5DCAD42075 Q38686628-E0D991EF-87DF-4545-8CFE-E469BD2A5AB8 Q38686630-D57B8F19-CA71-4324-9E41-676E71543A04 Q38741802-E8426860-6E99-42F9-85BB-30A1DD71B888 Q38845891-6C22FCB3-0868-46DA-A00D-A6A943969643 Q41669687-828DF4FF-F173-4947-877B-901E56089789 Q45392298-76C54EEB-6AA5-4749-AB5B-56F9E316EE2B Q47260008-FCCC1080-A54C-4CE4-80D3-DEC1E725909B Q47794057-9FD1B102-BC48-4E83-8B6B-2CCAD75E718A Q52603297-0558384E-7550-4754-98B1-32CAB2F56E31 Q52911366-7FF7FEC6-82E1-4B26-83D3-788E5447E2E7 Q54963093-9738FF52-A881-449D-BE98-31E2D3A0FFD7

P2860

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

http://www.wikidata.org/entity/Q37695495

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Eribulin mesylate in pretreate ...... ospective observational study.

@en

Eribulin mesylate in pretreate ...... ospective observational study.

@nl

type

label

Eribulin mesylate in pretreate ...... ospective observational study.

@en

Eribulin mesylate in pretreate ...... ospective observational study.

@nl

prefLabel

Eribulin mesylate in pretreate ...... ospective observational study.

@en

Eribulin mesylate in pretreate ...... ospective observational study.

@nl

P1433

Q37695495-07A69227-02CA-4C52-8F85-880B22473BA7

P1476

Q37695495-5D4B7698-A5D0-4DB9-A8EF-F93CBD0183B6

P2093

Q37695495-0576EA76-A5F1-43B0-8D3F-D1CBFBE3CBD0

Q37695495-1C09BF53-8141-4F57-B049-D7988118162A

Q37695495-2A33C71C-1A10-4B1D-8B3A-C459F5CD7FD3

Q37695495-31B0732C-6623-47D8-B4C4-655ED3A30624

Q37695495-400BBA74-4DB6-496E-83E9-E1419796D99F

Q37695495-512B4E6D-784E-4F47-B5DC-B7A2F5DDF2B9

Q37695495-738A0652-2728-407D-8C02-438F8AA26747

Q37695495-7B14C464-C8BC-4B26-99E4-F87378B412B2

Q37695495-B46B1BB5-3426-43EB-81F6-9111EB795DEE

Q37695495-CDA8AB75-E3D8-4229-9337-961A5FC32FEC

P2860

Q37695495-04AD1722-ABF9-49FD-8716-6A987125EDCF

Q37695495-080E8B6D-272C-4038-BFA6-2550CF386CF4

Q37695495-090C23E6-C086-4B7E-94ED-7A777B589E8F

Q37695495-2AE5976F-823E-4953-B4B3-5F9A6CB35619

Q37695495-30B67786-C4D3-4951-ABE9-F7C7A7000E91

Q37695495-33462D19-9DD5-44A1-870B-90E1DD338765

Q37695495-34C15A55-1CF2-4AC1-9775-A9A3D3231096

Q37695495-3C6CB4B4-4158-4771-B1F8-264A9DF01104

Q37695495-53746A6A-483A-44F2-9222-76CC69DEBCC0

Q37695495-5BE0F26D-5CFB-456F-8AB8-6C1E0DFD38CC

P304

Q37695495-67D02443-F392-4BA0-AB7D-CAA3F93E71E6

P31

Q37695495-78AAA2DB-F667-4B77-8EA8-61ACFD6F7AE6

P356

Q37695495-24E247ED-E01B-417C-94E3-04E0E8D20D8A

P433

Q37695495-30105F31-63DE-47C2-9256-4F56B4118BC7

P478

Q37695495-D4387843-FF7B-4CBA-94B9-6C7A08D3ABB3

P50

Q37695495-0B3E3213-E56B-4681-88DE-0D6D1AFC7FB4

Q37695495-1DCDABCB-C00E-448F-B820-E621E12682F0

Q37695495-A733B7D4-3CE5-45DD-8204-657EBDD4C23B

Q37695495-AB9416BF-745B-44E3-BC11-CA7609F77D52

Q37695495-DDD9CAB1-2723-4087-9AF2-DE3832DA2E1E

P577

Q37695495-3101AEE8-06A5-4B9F-BDDF-CD654BBF0320

P5875

Q37695495-58706B8F-B63B-43F3-A7D1-2113417FEF0D

P698

Q37695495-960893B7-3815-4407-8FDA-041A5A77E961

P921

Q37695495-05791A5E-4649-445B-86A5-3D239070C04D

P932

Q37695495-B6B034FA-F92E-4277-BADC-87EC1DCF0E07

P356

P1433

Journal of Cancer

P1476

Eribulin mesylate in pretreate ...... rospective observational study

@en

P2093

Alessandra Fabi

http://www.w3.org/2001/XMLSchema#string

Andrea Michelotti

http://www.w3.org/2001/XMLSchema#string

Angela Vaccaro

http://www.w3.org/2001/XMLSchema#string

Elisabetta Landucci

http://www.w3.org/2001/XMLSchema#string

Enzo Veltri

http://www.w3.org/2001/XMLSchema#string

Ida Pavese

http://www.w3.org/2001/XMLSchema#string

Ilaria Ferrarini

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Lucia Mentuccia

http://www.w3.org/2001/XMLSchema#string

Luigi Di Lauro

http://www.w3.org/2001/XMLSchema#string

P2860

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.

Treating breast cancer in the 21st century: emerging biological therapies

Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.

Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.

Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

P304

320-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.8748

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Isabella Sperduti

Giuseppe Tonini

Paolo Marchetti

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261604702

http://www.w3.org/2001/XMLSchema#string

P698

24723974

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3982178

http://www.w3.org/2001/XMLSchema#string